• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 11, 2017

View Archived Issues

Oncomed Pharmaceuticals' shares crumple over cancer trial miss, Bayer option termination

Oncomed Pharmaceuticals Inc. is embarking on an internal portfolio review in the wake of a phase II trial miss and a key partner loss Monday, news which pushed company shares (NASDAQ:OMED) 36.6 percent lower to close at $5.55 on Monday. Read More

Other news to note

Cellular Biomedicine Group Inc., of Shanghai, and GE Healthcare Life Sciences China, said they have established a strategic research collaboration to co-develop certain high-quality industrial control processes in chimeric antigen receptor T-cell (CAR-T) and stem cell manufacturing. Read More

SEC takes action on biopharma stock promotion scheme

In a sweeping enforcement action that could impact investment in small biopharma and med-tech companies for months to come, the SEC cracked down Monday on what it labeled as a fraudulent scheme in which investors were given the impression they were reading independent, unbiased analyses on investing websites when, in reality, the writers were secretly compensated for promoting the companies' stocks. Read More

Another biopharma joins IPO queue as Biohaven seeks $100M raise

Biohaven Pharmaceutical Holding Co. Ltd., a clinical-stage biopharma registered in the British Virgin Islands, filed an S-1 with the SEC for an IPO of up to $100 million. Read More

Nybo Therapeutics launches, aims MAbs at pancreatic cancer

LONDON – Technology commercialization specialist Puretech Health plc has launched start-up, Nybo Therapeutics, to discover and develop monoclonal antibodies that neutralize newly discovered immunosuppressive mechanisms in pancreatic cancer. Read More

Stack of biopharma bills looking for a ride through U.S. Congress

A spate of bills ranging from spurring generic competition to funding pediatric research was introduced last week just before the U.S. Congress turned the lights out for a two-week recess. Read More

Researchers confirm reversal of cellular aging

Korean researchers at Daegu Gyeongbuk Institute of Science and Technology (DGIST) have discovered a new mechanism through which senescence is controlled at the cellular level and identified a means by which that mechanism's function is modulated, offering the potential to reverse the aging process. Read More

Financings

Hemostemix Inc., of Blackfalds, Alberta, said it reached an agreement with Wood Capital Ltd. on a non-brokered senior secured debt financing of C$4.4 million (US$3.29 million) in one or more tranches. The agreement also contemplates that a non-brokered or brokered private placement or placements of a minimum of C$4 million to a maximum of C$8 million will also be completed. Read More

In the clinic

Roche AG, of Basel, Switzerland, said its Genentech unit reported that the global, randomized phase III ALEX study met its primary endpoint and showed that Alecensa (alectinib) as an initial (first-line) treatment significantly reduced the risk of disease worsening or death (progression-free survival) compared to the tyrosine kinase receptor inhibitor crizotinib (Xalkori, Pfizer Inc.) in people with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe